0.1811USD+9.76%Mkt Cap: 8.19M USDP/E: —Last update: 2026-06-01
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phas…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap8.19M USD
Enterprise Value6.89M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.21M USD
Revenue/Share—
Last Price0.1811 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.45
EPS (TTM)-0.25
EPS (Forward)—
52W Range
0.13200% of range33.66
52W High33.66 USD
52W Low0.1320 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE103.99%
ROA-1990.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.96M USD
CapEx (TTM)13.11K USD
FCF Margin—
FCF Yield—
Net Debt-465.17K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.15
Current Ratio0.96
Quick Ratio0.66
Book Value/Sh-0.3630 USD
Cash/Share0.0430 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.44.88M
Float29.07M
Insiders38.53%
Institutions3.29%
Short Interest
Short Ratio0.1d
Short % Float1.73%
Short % Out.1.25%
Shares Short562.36K
Short (prev mo.)1.99M
Technical
SMA 500.1959 (-7.6%)
SMA 2001.008 (-82.0%)
Beta0.76
S&P 52W Chg27.94%
Avg Vol (30d)14.08M
Avg Vol (10d)40.05M
Technical Indicators
RSI (14)41.6
MACD-0.0102
MACD Signal-0.0087
MACD Hist.-0.0015
BB Upper0.2310 USD
BB Middle0.1921 USD
BB Lower0.1533 USD
BB Width40.47%
ATR (14)0.0302 USD
Vol Ratio (20d)0.19x